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Abstract
DC deliver information regulating trafficking of effector T cells along T-cell priming. However, the role of pathogen-derived
motives in the regulation of movement of T cells has not been studied. We hereinafter report that amount of M tuberculosis
in the adjuvant modulates relocation of PLP139-151 specific T cells. In the presence of a low dose of M tuberculosis in the
adjuvant, T cells (detected by CDR3 BV-BJ spectratyping, the so-called ‘‘immunoscope’’) mostly reach the spleen by day 28
after immunization (‘‘late relocation’’) in the SJL strain, whereas T cells reach the spleen by d 14 with a high dose of M
tuberculosis (‘‘early relocation’’). The C57Bl/6 background confers a dominant ‘‘early relocation’’ phenotype to F1
(SJL6C57Bl/6) mice, allowing early relocation of T cells in the presence of low dose M tuberculosis. A single non-synonymous
polymorphism of TLR2 is responsible for ‘‘early/late’’ relocation phenotype. Egress of T lymphocytes is regulated by TLR2
expressed on T cells. Thus, pathogens engaging TLR2 on T cells regulate directly T-cell trafficking, and polymorphisms of
TLR2 condition T-cell trafficking upon a limiting concentration of ligand.
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Introduction
Trafficking of effector T cells plays a key role in the response to
pathogens, immunosurveillance and autoimmunity. T-cell activa-
tion is accompanied by a modification of the cell surface asset of
several molecules involved in cell adhesion and migration that are
consequently differentially expressed on naı¨ve, effector and
memory T cells [1].
The ability of cells of the innate immune system to ‘‘sense’’
pathogen-related moieties relies on Pattern-recognition receptors
(PRRs). Most PRRs are polymorphic in humans and mice, and
these polymorphisms bear differences in the control of infectious
pathogens [2]. DC express most, if not all, of the PRRs. Following
engagement of PRRs, DC increase their ability to present antigen
and activate T cells, and to secrete directive cytokines [3,4].
Simultaneously, they re-organize their asset of integrins, chemo-
kines and chemokine receptors relocating to the draining lymph
nodes (LN) to prime T cells [5]. To achieve an optimal
organization of the immune response, antigen presenting DC
transfer information of the site in which they had encountered the
antigenic moiety and of type of pathogen to T cells [6], regulating
integrin expression [7,8].
PRRs, however, are not uniquely expressed by DC or
macrophages and TLRs may have a general role in directing cell
movement, as supported by the observation that activation of
TLR2 and TLR9 regulates CD62L expression in-vitro and
modulates trafficking of B cells [9].
By using the CDR3 BV-BJ spectratyping (a PCR-based
technique also called ‘‘immunoscope’’, that allows to identify
antigen (ag)-specific, individual T-cell clones within a polyclonal
response on the basis of the CDR3 region of the TCR [10]) we
observed that trafficking of activated, PLP139-151 (p139)-specific
T cells of SJL mice is greatly affected by immunization [11]. Four
days after challenge with p139 in IFA enriched with 200
microgrammes/mouse of M tuberculosis (M tb) (herein, enriched
CFA), p139-specific T cells of the pre-immune repertoire (sharing
a typical set of TCRs) move to the LN draining the site of
injection; at the same time point, T cells of the induced repertoire
(characterized by a different TCR repertoire that include a public
TCRbeta CDR3 of BV10-BJ1.1 (97b length, herein BV10+ cells)
[12]) are primed in the draining LN, and 10–14 days after
challenge, they reach the spleen, where they replace cells of the
pre-immune repertoire.
Also, activated T cells express TLRs; it has been shown that
TLR2 acts as co-stimulator during T-cell activation [13,14], and
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interferes with T-cell polarization [15,16] and Treg/Th17 trans-
differentiation [17,18]. However, no data are available on the role
of pathogens and PRRs in trafficking of T cells.
As we having shown [11] that re-shuffling of the antigen -
specific TCR repertoire depends on the antigen, we hereinafter
report that trafficking of p139-specific T cells is regulated by M tb
in the adjuvant directly through TLR2 expressed on T cells.
Results
The Amount of M tb in the Adjuvant Modulates
Appearance of p139-specific T Cells
We immunized SJL mice with p139 in IFA containing 50
microgrammes/mouse of M tb (regular CFA), and monitored time
of appearance of the shared BV10+ cells in draining LN and spleen
by CDR3 BV-BJ spectratyping (the so-called ‘‘immunoscope’’),
mirroring the similar experiment performed after immunization of
mice with the same amount of peptide but in enriched CFA [11].
Results are shown in Fig. 1A.
All mice showed the presence of BV10+ cells in the draining LN
by day 4 post-immunization; the same cells were not detected in
any spleen at this early time point, similarly to what was observed
using enriched CFA as adjuvant [11]. BV10+ cells were detected in
approximately 90% of draining LN at day 14 post-immunization
[12]. Yet, we detected the BV10+ cells in the spleen of a minority
of the same mice (less than 30%, see also Fig. 1B, p = 0.03),
similarly to what we observe in mice challenged with IFA alone
(Fig. 1B), and in contrast to what was observed in mice immunized
with enriched CFA that consistently showed BV10+ cells in the
spleen at this time point [11]. This previous result is hereinafter
confirmed in Fig. 1B, where 5 out of 6 mice immunized with p139
in the presence of enriched CFA showed BV10+ cells in the spleen
at day 14 after challenge (p = 1). Fig. 1C shows that an inverse
relationship exists between the total number of p139-specific T
cells in LN and in the spleen at this time point after immunization
in the presence of a high amount of M tb (enriched CFA) in the
adjuvant, supporting the idea T cells move from LN to the spleen
around day 14 in these latter experimental conditions. Finally, at
day 28 post-immunization, BV10+ cells were detected in roughly
50% of the spleens of SJL mice immunized with p139, irrespective
of the amount of M tb in the adjuvant [11].
Thus, appearance of VB10+ cells in the spleen of SJL mice
immunized s. c. 2 weeks after challenge depends on the
administration of high amounts of M tb with the antigen.
Effect of Strain Background and TLR2 Genotype on
Sensitivity to Amount of M tb
We subsequently examined if the ‘‘sensor’’ for ‘‘amount of M tb’’
involved in the modulation of T cell appearance was TLR2, the
most important PRRs involved in recognition of M tb. A strain
lacking this molecule (B6129-Tlr2tm1kir/3 (herein B6tlr22) that
produces a non-functional, truncated form of TLR2) is available
on the B6 background, while the TCR/antigen pair (BV10+,
p139) we study is restricted to the SJL strain. In a first pilot
experiment we examined if F1 (SJLxB6wt) mice still use the public
BV10+ TCR in their response to p139. Two out of 4 F1
(SJLxB6wt) mice did so. In order to establish a threshold of
significance for antigen-driven expansion observed with the
‘‘immunoscope’’ in the F1 mice, we examined the variability of
the peak areas different from the one identifying the shared TCR,
in 5 F1 mice. Since the average stimulation index (RSI, see
Materials and Methods for a definition) regarding peaks repre-
senting TCRs which was not implied in the response to p139 was
160.225, we established an RSI $1.7 (avg+3 SD) as the
significant value for p139-driven expansion of the shared BV10+
TCR.
Seven F1 (SJLxB6wt) mice were immunized s. c. with p139 in
regular CFA, in two experiments. Two weeks later, we found that
BV10+ cells were detected in the spleen at the same frequency of
draining LN (3/7, Fig. 2A, left column), although we had used
regular CFA as adjuvant.
We then generated F1 (SJL6B6tlr22) mice that displayed a
functional TLR2 of SJL origin only. In two independent
experiments, 10 F1 (SJL6B6tlr22) mice were immunized with
p139 in regular CFA (Fig. 2A, right column) and 5 showed BV10+
cells responding to p139 in the LN 14 days post-immunization. In
these latter experiments, however, we failed to detect BV10+ cells
in the spleen of F1 (SJL6B6tlr22) mice (p = 0.03). Thus, the B6
genetic background provides a ‘‘highly sensitive’’, functionally
dominant sensor for M tb that confers an ‘‘early relocating’’
phenotype in the presence of a low dose of M tb to F1 (SJLxB6wt)
mice. This ‘‘sensor’’ appears to be TLR2.
PPD provides more selective ligands for TLR2 than the whole
M tb. We therefore examined if the same observations could be
replicated using PPD to supplement IFA. As shown in Fig. 2B, all
SJL mice challenged with p139 in the presence of 5 microgrammes
of PPD had BV10+ cells in LN and 75% of them had BV10+ cells
also located in the spleen (p= 0.2). When mice were challenged in
the presence of 0.5 microgrammes of PPD, BV10+ cells were
detected in the draining LN of all the mice but in the spleen of
only 1 out of 8 mice (p= 0.006). Afterwards, we examined the
effect of the TLR2 haplotype on mobilization of BV10+ cells upon
challenge in the presence of PPD (Fig. 2C). Seven out of 10 F1
(SJL6B6wt) mice challenged with p139 in the presence of 0.5
microgrammes of PPD showed an expansion of BV10+ cells in the
draining LN, and 5 also showed expansion of these cells in the
spleen (p = 0.6). When 12 F1 (SJL6B6tlr22) mice were immunized
in this experiment, 6 showed the expansion of BV10+ cells in
draining LN, but only 1 showed it in the spleen (p = 0.07). Thus,
we substantially reproduced the modulation of T-cell mobilization
due to whole M tb using PPD alone as a supplement, and we
observed the same genetic effect on appearance of effector T cells.
To formally prove that engagement of TLR2 is sufficient to
drive mobilization of T cells, we supplemented IFA with a mixture
of PAM2-(CSK)3 and PAM3-(CSK)3, (selective ligands for
TLR2/1 and TLR2/6 heterodimers, respectively). As shown in
Fig. 2D, the addition of PAM-(CSK)3 to IFA is sufficient to
mobilize p139-specific T cells in 7/8 mice, tested at 100 or 1 ng/
mouse, as compared to administration of p139 in IFA alone,
shown in Fig. 1B.
An important question is whether the dependence of T-cell
mobilization on TLR2 haplotype is limited to this model antigen
(or even only to T-cells carrying the studied CDR3-beta chain), or
rather this mechanism has a general relevance and applies to any
antigen. To address this point, in a separate experiment we
immunized 4 F1 (SJLxB6wt) mice and 5 F1 (SJLxB6tlr22) mice with
regular CFA. Two weeks later cells from draining LN and spleen
were recovered, labeled with CFSE and cultured in the presence
or absence (background) of PPD. After 3 days, the fraction of
CD3+ cells that had specifically divided in response to PPD was
determined as % of CFSElow CD3+ cells over total CD3+ cells.
Results, reported in Fig. 2E, showed that the two groups of F1
mice had the same number of PPD-specific T-cells in the LN. T
cells specific for PPD were present in consistent amount in 2 out of
4 spleens obtained from F1 (SJLxB6wt) mice, while spleens from all
5 F1 (SJLxB6tlr22) mice displayed very low numbers of T-cells
proliferating in response to PPD. Thus, it appears that TLR2
haplotype regulates the appearance in the spleen also of activated
TLR2 Regulates T Cell Trafficking
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T cells specific for allo-antigen(s) of bacterial origin, and the
observations reported here are not limited to self-reactive immune
responses.
It may be suggested that challenge in enriched CFA may
promote leakage of peptide and adjuvant from draining LN, and
that emergence of p139-specific T cells in the spleen, in this case,
may be the result of independent priming. However, results
previously reported [11] and those herein shown (time progression
in identification of T cells sharing the same TCR in LN first and
then in the spleen, an inverse relationship between p139-specific T
cells in draining LN and in the spleen, and dependence of
appearance on TLR2 haplotype) considered together, support the
hypothesis that the same T cells, defined by their TCR usage,
when activated in the LN, relocate to the spleen with different
kinetic depending on amount of M tb in the adjuvant and TLR2
haplotype.
A single Non-Synonymous Polymorphism of TLR2 is
Responsible for Early/late Appearance of T Cells
In order to examine the differences of TLR2 in B6 and SJL
strains reflected by mobilization of the T cells, we sequenced
TLR2 of SJL and determined its level of expression on activated T
cells and APC.
Figure 1. Amount of M tuberculosis in the adjuvant modulates appearance of p139-specific-T cells in the SJL strain. SJL mice were
immunized with p139 in IFA containing or not 50 or 200 microgrammes/mouse of M tuberculosis (regular or enriched CFA, respectively). In all the
figures, closed symbols refer to LN cells and open symbols to spleen cells. A) Time course of appearance of p139-specific BV10+ cells in LN and spleen
following challenge with antigen in regular CFA. BV10+, p139-specific T cells were measured by immunoscope in draining LN and spleen. B) Presence
of p139-specific BV10+ cells in the spleen at d 14 after s.c. immunization depends on the amount of M tuberculosis in the adjuvant. SJL mice were
immunized s.c. with 100 microliters of a 1:1 suspension of p139 in regular CFA (11 mice), in enriched CFA (6 mice) or in IFA alone (8 mice). Two weeks
later, mice were sacrificed and LN and spleen were examined for the presence of p139-specific BV10+ cells by immunoscope. Data are reported as
R.S.I., and each symbol represents LN or spleen of one mouse, and the dashed line represents the cut off value for positivity in SJL mice. c) The
number of p139 specific T cells in the spleen 14 d after challenge with peptide in enriched CFA is inversely related to the number of the same cells in
the LN. SJL mice were immunized s.c. with p139 in enriched CFA (4 mice). Two weeks later, cells from draining LN and spleen were stained with CFSE
and cultured in the presence or absence of 10 microgrammes/ml of p139. After 3 days, cells were recovered and stained with PE-labelled anti CD4
monoclonal antibody. p139-specific cells are calculated as CFSElow CD4+ cells in the ag-stimulated sample minus the number of the same cells in the
non-stimulated sample.
doi:10.1371/journal.pone.0055819.g001
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We sequenced the cDNA encoding for TLR2 from mice of SJL
and B6 strains bred in our facility, as described in the Materials
and Methods. The TLR2 sequence of B6 mice used in this study is
the same as the one deposited at the NCBI (http://www.ncbi.nlm.
nih.gov, accession numbers AK005043.1 for mRNA and
BAB23770.1 for a sequence). The sequence obtained from the
SJL mice displays 3 synonymous polymorphisms and one non-
synonymous polymorphism, 83Met (B6) to Ile (SJL), in the second
LRR (Fig. 3A).
We next evaluated if the TLR2 polymorphism determined a
modification of its level on the cell surface of APC or of activated
T cells. We immunized SJL, B6wt, F1 (SJL6B6wt) and F1
(SJL6B6tlr22) with CFA, collected cells from draining LN 4 days
after immunization, when specific T cells still appear to be
restricted to draining LN ( [11] and Fig. 1A). Cells were stimulated
with PPD and stained for CD3 and TLR2. Results are shown in
Fig. 3B and C. According to forward scattering and CD3
expression, LN cells were divided in APC, activated T cells and
naı¨ve T cells (Fig. 3B). The level of expression of TLR2 (Fig. 3C)
was the same on APC and activated T cells in SJL, B6 and
(SJL6B6wt) mice. A slightly lower expression (a difference of <
20% in the median fluorescence channel) was found on the surface
of T cells and APC obtained from F1 of SJL6B6tlr22.
In order to formally establish if the difference in sequence of
TLR2 regulates the mobilization of T cells in response to regular
CFA, we produced F1 mice having two copies of the TLR2 gene
of SJL origin (F1 (SJLts6B6ts)). The procedure is shown in Fig. 4.
‘‘B6ts/t2’’ mice (i.e. mice of B6 background heterozygous for
TLR2 of SJL (ts) and B6tlr22 (t-) origin) were bred with SJL mice,
producing two types of F1 littermates, (SJL6B6tlr22) and
(SJL6B6ts), the former having one copy and the latter two copies
of TLR2 of SJL origin. Results show that F1 mice (differing in
gene load of TLR2 of SJL origin) display the same phenotype, and
only 20% of the mice display a presence of these cells in the spleen
in both groups, in contrast to 50% of the mice showing it in the
LN. Thus, residue at position 83 (Met to Ile) of TLR2 is critical to
determine ‘‘late’’ versus ‘‘early’’ appearance phenotype, while its
gene load does not have a role.
T-cell Mobilization is Regulated by TLR2 Expressed on T
Cells
We next sought to understand if T-cell mobilization is regulated
by TLR2 expressed on APCs or directly by TLR2 expressed on T
cells.
In order to trace p139-specific T cells, we prepared a transgenic
mouse expressing the shared beta chain BV10-CASS SGS NTEV-
BJ1.1 on the SJL background (SJLBV10). To detect T cells
expressing the transgenic beta chain with available anti-BV10
monoclonal antibodies, we used the BV10 chain of the TCR type
2 haplotype as a backbone. Transgenic T cells proliferating in
response to p139 after immunization can be detected by flow
cytometry as BV10+ CFSElow cells (Fig. 5A).
We crossed SJLBV10 mice with B6wt or with B6tlr22. T cells from
these F1 mice were then transferred into naı¨ve F1 (SJLxB6wt) and
F1 (SJL6B6tlr22), and recipient mice were challenged with p139 in
regular CFA a week later. LN and spleen cells were collected
after14 days, stimulated with peptide and cells, proliferating in
response to p139, were measured as BV10+ CFSElow cells as
described in Materials and Methods.
In these experiments, transferred BV10+ T cells possess
functional TLR2 only of the SJL genotype (donors F1
Figure 2. Mobilization of T cells is strain and TLR2-dependent. F1 (SJLxB6wt), F1 (SJLxB6tlr2) (A, C) or SJL (B, D) mice were immunized with
p139 in IFA in the presence of the indicated amounts of killed M tb (A), or of PPD (B, C) or of a 1:1 w/w mixture of PAM2-(CSK)3 and PAM3-(CSK)3 (D).
The number of mice for each group is indicated in the figure. Fourteen days later mice were sacrificed and the presence of T cells carrying the public
TCR-beta chain in LN (closed symbols) and spleen (open symbols) was measured by immunoscope. Data are reported as RSI for the peak
corresponding to the public BV10 TCR-beta chain for each individual mouse. Dashed lines indicate the cut off value for positivity (established as
described in Results). E: 4 F1 (SJLxB6wt, circles) mice and 5 F1 (SJLxB6tlr22, triangles) mice were immunized with regular CFA in PBS. Two weeks later
cells from draining LN (full symbols) and spleen (open symbols) were recovered, labeled with CFSE and cultured in the presence or absence
(background) of PPD. After 3 days, the number of CD3+ cells that had specifically divided in response to PPD was determined as % of CFSElow CD3+
cells over total CD3+ cells in the PPD stimulated sample minus % of CFSElow CD3+ cells over total CD3+ cells in background sample.
doi:10.1371/journal.pone.0055819.g002
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SJLBV106B6tlr22), or of both strains (donors F1 SJLBV106B6wt);
the asset of TLR2 of APC and stromal cells is dictated by the
TLR2 haplotype of receiving mice. Results are reported in Fig. 5B.
Since the TCR locus of B6 mice also belongs to the type2
haplotype, we first established the background reading of spleen of
both F1 recipient mice immunized with p139. The number of
BV10+ CFSElow cells in the spleen after stimulation with p139 was
#55/104 BV10+ cells in 10 out of 11 mice (Fig. 5B), and we used
this as a threshold value.
When we transferred T cells obtained from F1
(SJLBV106B6tlr22) mice (having only TLR2 of SJL origin), the
number of BV10+ cells in the spleen of recipient mice was similar
to that observed in control non-transferred mice, irrespective of
the TLR2 haplotype of recipient mice (p = 0.6). On the other
hand, when transferred T cells had been obtained from F1
Figure 3. Identification of polymorphisms of TLR2 between SJL and B6 strains and expression of TLR2 on immune cells. A)
Comparison of the sequence of TLR2 of SJL and B6. The non-synonymous and synonymous polymorphisms are boxed. Base (first line) and aminoacid
(second line) sequences of B6 and the corresponding sequences (third and fourth lines, respectively) of SJL around the polymorphic residues are
reported. B) Identification of enriched activated T cells, naı¨ve T cells and APC in LN cells by scattering properties. SJL, B6wt, F1 (SJLxB6wt) and F1
(SJLxB6tlr22) mice were immunized with IFA containing 50 microgrammes/mouse of M tb.. 8 days later, mice were sacrificed and cells from draining
LN were loaded with CFSE and stimulated with PPD. After 3 days, cells were collected and stained with PE-labeled anti-CD3 monoclonal antibody. The
colours define cells examined for TLR2 expression in panel C. C) SJL, B6wt, F1 (SJLxB6wt) and F1 (SJLxB6tlr22) mice were immunized with IFA
containing 50 microgrammes/mouse of M tb. Eight d later, mice were sacrificed and cells from draining LN were stimulated with PPD. After 3 days,
cells were collected and stained with PE-labeled anti-CD3 mAb and with FITC labeled anti-TLR2 mAb. Expression of TLR2 was evaluated on high
scattering CD3+ cells (activated T cells, red line), low scattering CD3+ cells (naı¨ve T cells, shaded area) and CD32 cells (mostly APC, black line), as
shown in B.
doi:10.1371/journal.pone.0055819.g003
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(SJLBV106B6wt) mice that had TLR2 of both SJL and B6 origin,
75% of the spleens of recipient mice showed a number of BV10+
CFSElow cells significantly higher than in control mice (p = 0.006),
once again irrespective of the TLR2 haplotype of receiving mice.
Thus, appearance of T cells in the spleen 14 days after s. c.
immunization was modulated by TLR2 of transferred T cells,
while TLR2 expressed on APCs and stromal cells did not appear
to play a role.
Discussion
We herein report that the time by which antigen-specific T cells
appear in the spleen following priming in LN is modulated by
concentration of M tb in the adjuvant directly on activated T cells.
The modulation is strain-dependent and one non-synonymous
polymorphism between TLR2 expressed on T cells of SJL and B6
accounts for ‘‘late’’ versus ‘‘early’’ appearance phenotype.
An appropriate adaptive T-cell mediated immune response is
necessary to obtain clearance of the pathogen, preventing a
chronic evolution of the infection (e.g. [19]). In the present work,
we studied the appearance of T cells in the spleen following
priming in the LN, and used it as a marker of mobilization of T
cells. Further studies are required to assess if TLR2 directly
influences also trafficking of T cells to other sites, or if a passage
through the spleen is necessary to licence T cells to further diffuse
to peripheral organs. The microenvironment of the spleen has
distinct properties with respect to that of LN [20], and trafficking
through the spleen seems necessary for myelin-specific T cells to
acquire encephalitogenic properties [21]. We have observed that
T cells display some differences in homing to the CNS upon
encephalitogenic challenge that depend on the TLR2 haplotype
(manuscript in preparation). However, invasion of the CNS and
the following EAE depend upon the administration of a high dose
of CFA, and these data were obtained in experimental conditions
different from those used in this work. Therefore, at present we
cannot establish a direct link between the observations reported
here about the role of M tb and TLR2 in modulating relocation of
p139-specific T cells from LN to spleen, and T-cell trafficking into
the CNS.
It has recently been reported that Central Nervous System-
specific T-cell blasts need to traffic through the lung in order to
acquire migratory properties that allow them to home to the
spleen first and then to the CNS [22]. Our observations reported
here suggest that components of bacterial origin, administered in
our experimental model with the adjuvant, are needed for T cells
to be licensed to move to the spleen. In the case of T cells activated
in vitro, the passage through the lungs may provide the possibility
to encounter bacteria able to engage TLR2 and thereby acquire
the appropriate migratory phenotype. Endogenous ligands of
TLR2 [23] may also be involved in the modulation of trafficking
properties of activated T cells, and regulation of these endogenous
ligands may promote or protect from CNS invasion.
TLRs are key molecules for the determination of the Th
phenotype. Activation of DC via TLRs plays a major role in the
polarization of naı¨ve T cells, and direct engagement of TLR2 on
activated T cells modulates the trans-differentiation between
FoxP3+ and Th17 cells [17], allowing the immune response to
adapt to the presence of infectious agents without maintaining
constitutively a pro-inflammatory aptitude.
Modulation of the trafficking properties of immune cells is an
effect of PRRs engagement, with the paramount example of the
well-studied cycle of DC [5]. Activation of TLR2 and TLR9
regulates CD62L expression in B cells modifying the distribution
of B cells between spleen and LN [9]. Here, we report that TLR2
also regulates the time by which antigen-specific T cells mobilize
in vivo, showing that pathogen-derived motives can modulate the
trafficking properties of T cells without mediation by APCs.
A trivial explanation of our observation would be that TLR2
polymorphism and M tb in the adjuvant influence the down-
regulation of CD62L (as it occurs in B cells [9]) and, consequently,
the relocation of activated T cells to the spleen. However, this is
not the case; In fact, while the haplotype of TLR2 has some effect
on the down-modulation of CD62L on activated T cells, the
amount of M tb in the adjuvant does not regulate the down-
modulation of CD62L in the SJL strain (not shown). We also
observed that the level of expression of Sphingosin 1P-R1 (a
relevant molecule involved in egress of T lymphocytes from the
LN [24]) does not vary depending on the TLR2 polymorphism.
Thus, neither of these 2 molecules appears to represent the
common mechanism underlying the observations herein reported.
T-cell activation is accompanied by a modification of the cell
surface asset of many molecules involved in the regulation of cell
trafficking. Several of these molecules are differentially expressed
Figure 4. Mobilization of T cells depends on the polymorphism
of TLR2. Upper section: transfer of TLR2 of SJL onto B6 background.
SJL mice (homozygous for TLR2 of SJL, ts+/+) mice were crossed with
B6tlr22 (t-). F1 mice (genotype ts/t-) were then backcrossed with B6tlr22
and F2 mice of genotype ts/t- are further backcrossed with B6tlr22
generating F3 mice ts/t- that share <90% of their genome with B6wt.
These latter mice (B6ts/t2) were crossed with SJL mice to generate TLR2-
heterozygous F1 (SJLtsxB6t2) and TLR2-homozygous F1 (SJLtsxB6ts)
mice. Lower section: these two groups of littermates were immunized
with p139 in regular CFA and 14 days later the presence of T cells
carrying the public TCR-beta chain in LN (closed symbols) and spleen
(open symbols) was examined by immunoscope, as described above.
Ten mice per group were examined, and mice of each group derived
from two distinct (B6ts/t26SJL) couples. Data are reported as RSI for the
peak corresponding to the public TCR-beta chain for each individual
mouse. The cut off value for the RSI at 1.7 is indicated.
doi:10.1371/journal.pone.0055819.g004
TLR2 Regulates T Cell Trafficking
PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e55819
on naı¨ve, effector and memory-T cells, and regulate the trafficking
properties of each T-cell group. Further studies will be needed to
establish which, among the molecules regulating T-cell trafficking,
are modulated by TLR2 to lead to the differences in T-cell
mobilization reported here.
A large array of PRRs is expressed in T-cells, and the
integration of signals coming from each PRR determines the final
effect of encounters with microorganisms able to interact with
several of them. Molecules belonging to the family of NOD-like
receptors play an important role in the recognition of Mtb.
Analogous to TLRs, it has been reported that molecules belonging
to this family are also expressed in T cells (see, e.g., [25,26]), with
conflicting evidences about their role [27,28]. Nod1 and Nod2
interplay with TLRs in macrophages [29], and, more relevant to
the present model, Nod1 cooperates with TLR2 to promote the
activation of CD8+ cells [30]. It will be of interest to assess if
molecules belonging to this family co-operate with TLR2 also to
modulate T cell mobility.
The time by which effector-T cells reach the site of infection is
crucial for an effective pathogen control. Polymorphisms of TLRs
have been associated to a susceptibility or resistance to infectious
diseases (e.g. [2]). In several cases, a link between polymorphism
and Th polarization has been demonstrated and suggested to
sustain differences in pathogen control. TLR2 polymorphism
83Met/Ile alters the promptness of mobilization of T cells upon
limiting concentration of the ligand, suggesting another mecha-
nism for polymorphisms of PRRs to affect the control of infections.
Mobilization of self-reactive T cells from survival niches also
plays an important role in the pathogenesis of autoimmune
diseases, in particular of those in which a poorly predictable degree
of relapses strongly influences the final outcome of the disease. It is
a common observation that the occurrence of infections often
Figure 5. Appearance of T cells in the spleen is regulated by TLR2 expressed on T cells. A) Detection of p139-specific T cells in SJLBV10
mice. One SJLBV10 mouse (at the 6th backcross onto SJL background) was immunized s. c. with p139 in regular CFA, as described above. Ten days later
LN cells were obtained, stained with CFSE and cultured in the presence or absence of p139. The number of BV10+, p139-specific T cells in the draining
LN is measured as the number of CFSElow BV10+ cells in the ag-stimulated sample, minus the number of the same cells in the non-stimulated sample.
B) T cells were enriched from the spleen of naı¨ve F1 mice of (SJLBV106B6wt) or (SJLBV106B6tlr22), and transferred i. p. into naı¨ve F1 mice of (SJL6B6wt)
or (SJL6B6tlr22). A week later, recipient mice were immunized s. c. with p139 in regular CFA, and after, further 14 days, cells from LN and spleen were
prepared, and the presence of BV10+, p139-specific T cells was measured as described in Fig. 4a. The 11 non-transferred mice were 6 F1 (SJL6B6wt)
mice and 5 F1 (SJL6B6tlr22) mice, all challenged with p139 in regular CFA. Data are expressed as the number of BV10+, CFSElow, p139-specific cells/104
BV10+ cells.
doi:10.1371/journal.pone.0055819.g005
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leads to flares of autoimmune diseases, and a prevention of the
release of T cells from LN is now an effective therapy [24].
Bacteria colonising mucosal surfaces [31] also provide an essential
contribution to the pathogenesis of autoimmune disorders by
regulating the polarization of T helper cells. Our observation adds
a further mechanism to the role of infections in autoimmunity,
suggesting that products derived from bacteria may contribute to
mobilization of activated self-reactive T cells from niches that
allow them to escape natural (e.g., the spontaneous remission
during Multiple Sclerosis) or therapy-induced (as in Rheumatoid
Arthritis [32]) control.
Several environment-derived and endogenous stimuli cooperate
during activation of T cells by engaging a variety of PRRs, and
thereby leading to effective control of infectious agents, or to their
chronic containment, or in some cases to self-reactivity. The ability
of pathogens engaging TLR2 directly on activated T cells through
a polymorphic site, to regulate trafficking of CNS-specific, effector
T cell in vivo has been the subject of our study.
Materials and Methods
Mice, Peptide and Immunization
Breeding couples for SJL, C57Bl/6 (B6wt) mice and B6129-
Tlr2tm1kir/3 (B6tlr22) were purchased from Charles River, Calco,
Italy, and bred in the animal housing facility of the Universita’
Cattolica del S. Cuore in Rome. B6 mice, heterozygous for TLR2
of SJL (B6ts/t2), were generated as described in Fig. 4, by back-
crossing F1 (SJLxB6tlr22) onto B6tlr22 for 2 generations.
PLP139-151 (Ser 140 [33]) was purchased from PRIMM
(Milan, Italy) and was .95% pure, as determined by HPLC and
mass-spectroscopy.
Mice were immunized subcutaneously (s. c.) with 50 micro-
grammes/mouse of p139 in PBS, emulsified 1:1 with Incomplete
Freund’s Adjuvant (IFA), complete (CFA) Freund’s adjuvant (CFA
is IFA containing 1 mg/ml of killed and heat dried M. tb H37RA,
i.e. each mouse received 50 microgrammes of M. tb H37RA) or
IFA containing 4 mg/ml of killed and heat dried M. tb H37RA
(enriched CFA, i.e. each mouse received 200 microgrammes of M.
tb H37RA) (Sigma-Aldrich, St Louis, MO, USA) in a final volume
of 100 microliters/mouse, or in the conditions indicated in
Figure 2. All experimental procedures involving animals were
approved by the internal Ethics Committee.
TLR2 Sequencing
cDNA was prepared from LN cells of SJL and B6 mice and
sequenced from PCR products using 5 pairs of primers covering its
sequence from b376 (aa 8) to b2706 (aa 784), using a Genetic
Analyzer 3130 (Life Technologies, The Netherlands) and analyzed
with Chromas Lite 2.1 free software. To sequence TLR2, cDNA
obtained from spleen cells was submitted to RT-PCR (35 cycles)
using five couple of primers (see below). PCR products were
purified using a gel extraction kit (Qiagen), and conjugated with
the BigDYE 3.1 (Life Technologies, The Netherlands), in
compliance with manufacturer’s instructions.
Primer Pairs
TLR2 FW1 366 tctttggctcttctggatcttggtg
TLR2 REV1aaaaatctccagcaggaaagcagac1005
TLR2 FW2886gctgggctgacttctctcaatg
TLR2 REV2acagtcgtcgaactctacctcc 1214
TLR2 FW31199 agagttcgacgactgtaccctc
TLR2 REV3gaatgcacgtttttaccacccg1720
TLR2 FW41623acttttcatccgatgcccgac
TLR2 REV4acccaatgggaatcctgctcac 2318
TLR2 FW52271 tgctatgatgcctttgtttcc
TLR2 REV5ttgcagttctcagatttaccc 2698
Numbers refer to the deposited sequence (http://www.ncbi.
nlm.nih.gov, accession numbers AK005043.1).
T-cell Receptor Repertoire Analysis
Repertoire analysis was performed as previously described
[12,34,35]. Briefly, 56106 LN cells or 107 spleen derived cells/well
were cultured in the presence or absence of 10 microgrammes/ml
of p139 for three days in RPMI-1640 medium (Sigma- Aldrich, St
Louis, MO, USA) supplemented with 2mM L-glutamine, 50
microM 2-ME, 50 microgrammes/ml gentamicin (Sigma- Aldrich,
St Louis, MO, USA), and 1% mouse serum. Three days later, cells
were collected, washed in PBS and resuspended in RLT. Total
RNA was isolated from cell suspensions using RNeasy Mini Kit
(Qiagen GmbH, Hilden, Germany) according to the manufactur-
er’s instructions. cDNA was synthesized using an oligo-dT primer
(dT15) (Gibco BRL Life Technologies, Basel, Switzerland). cDNA
was subjected to PCR amplification using a common Constant (C)
beta primer (CACTGATGTTCTGTGTGACA) in combination
with the variable beta (BV) primers previously described [12].
Using 2 microliters of this product as a template, run-off reactions
were performed with a single internal fluorescent primer for each
BJ tested (previously described [12]). These products were then
denatured in formamide and analyzed on an Applied Biosystem
3130 Prism using Gene-mapper v4.0 software (Applied Biosystem,
Foster City, CA, USA). Results are also reported as R.S.I. (rate
stimulation index= normalized peak area obtained from cells
stimulated with Ag/normalized peak area of non-stimulated cells).
TLR2 Staining
Surface expression of TLR2 was determined by FACScan. SJL,
B6wt, F1 (SJL6B6wt) and F1 (SJL6B6tlr22) mice were immunized
with regular CFA. Four days later, LN cells were obtained, stained
or not with CFSE and stimulated with PPD for 3 days. Cells were
then divided in aliquots and labelled with the Rat antimouse
AntiCD282 (AbD Serotec Raileigh NC (USA)) mAb and PE-
labelled anti CD3 mAb (BD Bioscience Pharmingen, San Diego,
CA, USA) and read on a BD FACScan flow cytometer.
Preparation of BV10 Transgenic Mice
In our previous work [12] we identified a CDR3-beta chain
(BV10-BJ1.1 of sequence CASS SGS NTE) consistently expressed
on T cells specific for p139 in the SJL mouse. In order to have a
reliable source of p139-specific T cells carrying this rearrange-
ment, we prepared a transgenic mouse carrying a gene encoding
for its TCR-beta chain using the BV10 sequence of the TCR2
haplotype as a backbone, to identify cells expressing the transgene
by available anti-BV10 antibodies and vector pP142b8AR (a kind
gift from H. Pircher [36]).
Founder transgenic mice were prepared at PolyGene AG
(Rumlang, CH). Briefly, the gene segment encoding for BV10-
CASS SGS NTE-BJ1.1 was inserted into the pP142b8AR vector.
The resulting TCR-beta chain was cloned into a plasmid
harboring this T-cell receptor beta chain (TCRb) cDNA driven
by the H-2K promoter/immunoglobulin heavy chain enhancer
(pHSE3’-tgbeta). A 6.3 kbp DNA fragment from pHSE3’-tgbeta
was excised with the restriction endonuclease XhoI. The fragment
was purified from SeaKem GTG agarose (avoiding exposure to
UV light) using the Qbiogene Geneclean Spin kit, dialysed 24 h
against 2 l microinjection buffer (10 mM Tris.HCl pH 7.2,
0.1 mM EDTA), and finally diluted to a concentration of
1.1 ng/ml. In four distinct rounds, the DNA was injected into
B6N-derived zygotes. For this purpose, B6N female mice were
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obtained from Charles River WIGA Sulzfeld, superovulated at 45
to 47 days of age and mated in the PolyGene mouse facility to
B6N breeder males, originally also obtained from Charles River.
Injected zygotes were cultivated overnight and transferred into
pseudopregnant B66CBA F1 females, also from Charles River.
Animals were kept in individually ventilated cages.
Tail DNAs of 3 out of 46 littermates were found positive for the
transgenic TCR-beta chain. The 3 mice were mated with the B6N
breeder and a transgene-positive pup was selected as founder of
the colony.
The founder was then transferred to the housing facility of the
Catholic university and mated with B6 mice to establish a founder
colony of transgenic mice on the B6 background. Once the colony
was established, we back-crossed the transgenic TCR BV10 chain
from B6 to SJL mice. All the experiments reported in the present
work and involving VB10-transgenic mice were performed using
mice that had been back-crossed for at least 6 generations into the
SJL background (herein SJLVB10), in most cases 9 generations or
more.
Transgenic mice were bred on a RAG1/RAG2wt background
to allow free rearrangement of the alpha-chain. Naı¨ve heterozy-
gous SJLBV10 mice express the transgenic beta chain on 62–68%
of both CD4+ and CD8+ cells. Confirming results obtained in wild
type SJL (SJLwt), transgenic BV10+ T cells do not participate in the
response to p139 that arises spontaneously in the SJL mouse [11]
but are activated only following immunization with peptide
antigens. BV10+ T cells that divided in response to in-vitro
stimulation with p139 are 15% and 23% of total BV10+ cells at
day 4 (not shown) and 10 after immunization, respectively (see also
Fig. 4A of the main text). Frequency of p139-specific precursors
could be estimated to be between 0.5 and 0.15% of BV10+ cells in
the naı¨ve SJLBV10 mouse.
In order to identify p139-specific VB10 transgenic cells we
followed the protocol described in [11]. Cells from SJLVB10 mice
were stained with CFSE (Invitrogen, Eugene, OR, USA) and
stimulated in vitro with p139. Three days later cells were stained
with a PE-labelled anti mouse BV10 mAb (BD Bioscience
Pharmingen, San Diego, CA, USA). T cells expressing the BV10
transgenic chain and recognizing p139 were detected as BV10+
CFSElow cells (Fig. 5A) on a BD FACScan flow cytometer.
Transfer of Naı¨ve T Cells
SJLVB10 mice were mated with B6wt or B6tlr22 and spleen cells
were prepared from 7–10 week old naı¨ve F1 mice. T cells were
enriched by depleting spleen adherent cells and B220+ cells, using
anti-B220 MACS selection Kit (Milteny Biotech GmBH, Bergish
Gladbach, Germany). The final population was composed of 83%
CD4+ or CD8+ cells and the fraction of BV10+ cells was 49.8%.
Five6106 enriched T cells were transferred i. p. into naı¨ve mice.
One week later recipient mice were immunized as described above
and sacrificed 14 d later. Cells from draining LN and spleen were
stained with CFSE, cultured for 3 days in the presence (test) or
absence (control) of p139 and stained with PE-labelled anti BV10
mAb. The number of transgenic T cells specific for p139 was
calculated as the number of BV10+ CFSElow cells in the sample
stimulated with p139 minus the number of the BV10+ CFSElow
cells in the control sample, both values normalized to 104 total
VB10+ cells.
Statistical Analysis
Data were compared using two-tailed Fisher exact test.
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